Mesoblast Ltd

Explore Mesoblast Limited’s cutting‑edge regenerative therapies, its ASX stock dynamics, and future growth prospects for investors and biotech professionals.

Mesoblast Limited, a biotechnology company, has announced its financial results and operational updates, highlighting the successful FDA approval and commercial launch of its product Ryoncil, a treatment for steroid-refractory acute graft-versus-hos…